Biotech
-
Thomas Smeenk Discusses the Intersection of Hemostemix’s NCP Treatment and Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, CEO, and President…
-
Cardiol Furthers Clinical Trials to Advance Disruptive Cannabidiol-Based Therapies for Heart Disease
Heart disease continues to be a leading cause of death globally. According to Cardiol Therapeutics Inc. (NASDAQ: CRDL…
-
Promising Advancements in Gene Therapy are Leading to Potential Investment Opportunities
Today’s discussion is about a topic that fascinates me even though I can say that I do not…
-
Jon Gluckman of Sixth Wave Innovations Discusses Its Lithium and Gold Extraction Technology
In this InvestorIntel interview during PDAC 2023, Tracy Weslosky talks to Sixth Wave Innovations Inc.’s (CSE: SIXW |…
-
Valeo Pharma Impresses Again with 210% Quarterly Year-over-Year Revenue Growth
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”) just released their FQ1/2023 earnings results and impressed again.…
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Steve Saviuk, CEO of Valeo Pharma, Discusses Promising Results of COVID-19 Drug Sabizabulin and Revenue Growth in 2023
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and…
-
Zentek’s ZenARMOR is potentially a major breakthrough in the US$23.8B+ Global Anti-Corrosion Coatings Market
The anti-corrosion coatings market may not sound very glamorous, but it is a multi-billion dollar business. According to…
-
Valeo Pharma’s CEO Steve Saviuk Talks about Record FQ4 & F2022 Revenue Up 274% & 105%, Respectively
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO,…
